Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | TBK1 | Q9UHD2 | 4/20 | 0.42 |
| ▸ | TAS2R8 | Q9NYW2 | 1/20 | 0.41 |
| ▸ | WNT1 | P04628 | 1/20 | 0.40 |
| ▸ | GSK3B | P49841 | 1/20 | 0.40 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.40 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.39 |
| ▸ | HPGD | P15428 | 2/20 | 0.39 |
| ▸ | CLK2 | P49760 | 4/20 | 0.38 |
| ▸ | LRRK2 | Q5S007 | 4/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23945349 | 0.82 | OGA (0.46) | TBK1WNT1GSK3BDYRK1AHPGD | |
| SCHEMBL23945144 | 0.82 | OGA (0.46) | TBK1WNT1GSK3BDYRK1AHPGD | |
| SCHEMBL4291220 | 0.71 | HTT (0.55) | HTTTAS2R8PTPN1HPGDALDH1A1 | |
| SCHEMBL30627017 | 0.70 | HPGD (0.56) | WNT1GSK3BDYRK1AHPGDALDH1A1 | |
| SCHEMBL4285440 | 0.69 | OGA (0.53) | HTTTBK1GSK3BDYRK1AHPGD | |
| SCHEMBL29757925 | 0.69 | ACHE (0.49) | TBK1CLK2LRRK2 | |
| SCHEMBL26790003 | 0.66 | CLK2 (0.50) | HTTTBK1HPGDCLK2LRRK2 | |
| SCHEMBL26151737 | 0.66 | CLK2 (0.50) | HTTTBK1CLK2LRRK2KMT2A | |
| SCHEMBL25730750 | 0.65 | HPGD (0.87) | PTPN1HPGDALDH1A1MEN1KMT2A | |
| SCHEMBL26790000 | 0.65 | ALDH1A1 (0.48) | HTTTBK1GSK3BDYRK1AHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11352350-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2022-06-07 | — | — | US | disclosed |
| US-20210323952-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2021-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11352350-B2 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK1 | HTT 2464/4885TBK1 9/4885TAS2R8 3486/4885 |
| US-20210323952-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | HTT 2464/4885TBK1 9/4885TAS2R8 3486/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.